Indicated for the management of obesity, including weight loss and maintenance of weight loss, and should be used in conjunction with a reduced calorie diet.
Serotonin-Noradrenaline Reuptake Inhibitor; Appetite Suppressant
Sibutramine produces its therapeutic effects by inhibition of norepinephrine (NE), serotonin (5-hydroxytryptamine, 5-HT), and to a lesser extent, dopamine reuptake at the neuronal synapse. By inhibiting the reuptake of these neurotransmitters, sibutramine promotes a sense of satiety and decrease in appetite, thereby reducing food intake. Data from animal studies also suggest that sibutramine may also increase energy expenditure through thermogenic effects in both the basal and fed states, but this has not been confirmed in humans. Sibutramine and its major pharmacologically active metabolites (M1 and M2) do not act via release of monoamines.
ORAL Obesity: Adult: Initially, 10 mg daily in the morning. Re-evaluate treatment in patients whose wt loss is <2 kg in the 1 st4 wk of treatment. May increase dose to 15 mg daily. Reassess 4 wk later. Discontinue treatment if wt loss Is still <2 kg. Max: 15 mg daily.
1,2-Benzodiazepine The risk or severity of adverse effects can be increased when 1,2-Benzodiazepine is combined with Sibutramine.
Abacavir Abacavir may decrease the excretion rate of Sibutramine which could result in a higher serum level.
Abametapir The serum concentration of Sibutramine can be increased when it is combined with Abametapir.
Abciximab The risk or severity of hemorrhage can be increased when Sibutramine is combined with Abciximab.
Acebutolol The serum concentration of Acebutolol can be increased when it is combined with Sibutramine.
History of cerebrovascular disease. History of CV disease, including history of coronary artery disease, history of stroke or transient ischaemic attack, history of heart arrhythmias, history of congestive heart failure, history of peripheral arterial disease & uncontrolled hypertension. History of eating disorders (e.g. anorexia nervosa & bulimia nervosa); bipolar disorder, Tourette’s syndrome, hyperthyroidism, phaeoch romocytoma, benign prostatic hyperplasia; history of drug or alcohol abuse. Pregnancy, lactation. Severe renal or hepatic impairment. Hypertension; narrow-angle glaucoma; seizures; history of gallstones; family history of motor or verbal tics. Should not drive or operate machinery. Mild- moderate renal impairment. History of depression. History of hypertension, coronary artery disease, congestive heart failure, arrhythmias or stroke. Monitor BP & heart rate.
Dry mouth, drowsiness, dizziness, rhinitis, depression, emotional lability, migraine, skin rash, mydriasis, insomnia, constipation, diarrhoea, peripheral oedema, menstrual disorders.
Nevertheless, this medicationshould be avoided whenever possible during pregnancy, as there is little information on its effects. Because there is no published experience with sibutramine during breastfeeding, an alternate therapy may be preferred, especially while nursing a newborn or preterm infant. Information on the effect of sibutramine on serum prolactin is somewhat conflicting.
Store in cool & dry place below 30°C, protect from light & moisture. Keep out of reach of children.
.png&w=384&q=75)